Clinical trials: Venous
Arthroplasty, Replacement, Thromboembolism
Pradaxa (Dabigatran Etexilate 220 mg/q.d. in the General Population After Hip or Knee Replacement Surgery
An observational cohort study on safety and efficacy of the 220 mg dose Pradaxa to generate additional data in predefined sub populations of patients at increased risk of bleeding or VTE
- Trial name
- NCT00846807
- Where
- 112 sites in Austria, France and 7 more
- Volunteers
- 5,476 people
- Sponsor
- Boehringer Ingelheim
Venous Thrombosis, Deep Vein Thrombosis
Deep Vein Thrombosis Treatment With the Oral Direct Factor Xa Inhibitor Rivaroxaban in Patients Using a Strong CYP 3A4 Inducer
This is a multicenter, cohort study evaluating an adapted rivaroxaban dose regimen in patients with acute, proximal deep-vein thrombosis (DVT) or acute pulmonary embolism (PE) who concomitantly use a strong cytochrome P450…
- Trial name
- NCT00786422
- Testing
- Rivaroxaban (Xarelto, BAY59-7939)
- Where
- 16 sites in Australia, Austria and 7 more
- Volunteers
- 25 people
- Sponsor
- Bayer
Symptomatic Venous Outflow Obstruction in the Iliofemoral Vein
VIVO Clinical Study
The purpose of the VIVO Clinical Study is to evaluate the safety and effectiveness of the Zilver® Vena™ Venous Stent in the treatment of symptomatic iliofemoral venous outflow obstruction.
- Trial name
- NCT01970007
- Testing
- Zilver Vena Venous Self-Expanding Stent
- Where
- 30 sites in United States, Taiwan
- Volunteers
- 243 people
- Sponsor
- Cook Research Incorporated
Leg Ulcers
Biatain Ibu vs. Biatain in Painful Chronic Venous Leg Ulcers
The objective of this investigation is to demonstrate the effectiveness and safety of Biatain Ibu non-adhesive foam dressing compared to Biatain non-adhesive foam dressing.
- Trial name
- NCT00627094
- Testing
- Biatain, Biatain Ibu
- Where
- 13 sites in Denmark, France and 2 more
- Volunteers
- 120 people
- Sponsor
- Coloplast A/S
Heart Failure
The Effect of an Azygos Vein Coil on Defibrillation Threshold
When implantable cardiac defibrillators are implanted (ICDs), the defibrillation threshold (DFT), of the amount of energy required to effectively terminate life-threatening arrhythmias is determined.
- Trial name
- NCT00798174
- Testing
- Standard configuration vs. azygos coil
- Where
- United States
- Volunteers
- 32 people
- Sponsor
- Washington University School of Medicine
PICC, Central Venous Catheter
Complications Associated With Central Venous Access in the NSICU: PICC vs CVC
The goal of this study is to determine whether Peripherally Inserted Central Catheter or Centrally Inserted Venous Catheters have lower complication rates in the Neuroscience Intensive Care Unit.
- Conditions
- PICC, Central Venous Catheter, Central Line, Neuro ICU
- Trial name
- NSPVC (NCT02314520)
- Testing
- peripherally inserted central catheter, centrally inserted central catheter
- Where
- United States
- Volunteers
- 152 people
- Sponsor
- Milton S. Hershey Medical Center
Diabetic Macular Edema
Multiple Dose Safety and Efficacy of LKA651 in Patients With Diabetic Macular Edema
The primary objectives of this study were to evaluate the safety and efficacy of LKA651 in patients with macular edema from diabetic macular edema (DME),
- Trial name
- NCT03927690
- Testing
- LKA651, Lucentis
- Where
- 22 sites in United States, Germany and 3 more
- Volunteers
- 91 people
- Sponsor
- Novartis Pharmaceuticals
Cervical Cancer, Endometrial Cancer
Fondaparinux in Preventing Blood Clots in Patients Undergoing Surgery for Gynecologic Cancer
RATIONALE: Fondaparinux may help prevent blood clots from forming in patients who are undergoing surgery for gynecologic cancer.
- Conditions
- Cervical Cancer, Endometrial Cancer, Fallopian Tube Cancer, Ovarian Cancer
- Trial name
- NCT00381888
- Testing
- fondaparinux sodium
- Where
- 2 sites in United States
- Volunteers
- 44 people
- Sponsor
- Masonic Cancer Center, University of Minnesota
Atrial Fibrillation, Heart Valve Diseases
Prolongation of the Interval Between Monitoring of Warfarin in Stable Patients
Patients with mechanical heart valve prosthesis or with irregular beat (atrial fibrillation) have a high risk of blood clot formation. Such clots can result in a stroke.
- Conditions
- Atrial Fibrillation, Heart Valve Diseases, Venous Thrombosis
- Trial name
- NCT00356759
- Where
- Canada
- Volunteers
- 250 people
- Sponsor
- Hamilton Health Sciences Corporation
Hemorrhoids, Hemorrhoidal Disease
War-Drill Model Guided Treatment of Hemorrhoids With Nimsai Herbal (NAJ)
This study investigated a new understanding of hemorrhoid formation and evaluated a novel systemic treatment. For 200 years, hemorrhoids were conventionally understood as isolated swollen veins.
- Trial name
- NAJ (NCT07034820)
- Testing
- Nimsai Herbal
- Where
- Turkey (Türkiye)
- Volunteers
- 300 people
- Sponsor
- Nimsai Academia
Varicose Veins
Varithena Versus Endothermal Ablation of the Great Saphenous Vein (VERITAS)
The purpose of this study is to observe insights into the benefits of Varithena compared to Endothermal Ablation (ETA) in the treatment of the great saphenous vein.
- Trial name
- VERITAS (NCT05312970)
- Testing
- Varithena®, FDA-approved Endothermal Ablation (ETA) systems
- Where
- 9 sites in United States
- Volunteers
- 43 people
- Sponsor
- Boston Scientific Corporation
End Stage Renal Disease, AV Fistula
Safety and Efficacy Study of the Venous Window Needle Guide to Access Arteriovenous (AV)Fistulae
The SAVE Study will evaluate the safety and efficacy of the Venous Window Needle Guide in achieving access of a deep, un-cannulatable arteriovenous fistula to complete hemodialysis as prescribed.
- Conditions
- End Stage Renal Disease, AV Fistula, Kidney Failure
- Trial name
- SAVE (NCT01471041)
- Testing
- Venous Window Needle Guide
- Where
- 2 sites in United States
- Volunteers
- 54 people
- Sponsor
- Vital Access Corp.
Atrial Fibrillation
Left Atrial Mechanical Function Improvement After Atrial Fibrillation Catheter Ablation
The objective of the study was to estimate the efficacy of telmisartan and amlodipine combination on the restoration of left atrial mechanical function after atrial fibrillation catheter ablation.
- Trial name
- NCT02734355
- Testing
- Telmisartan 80 mg and amlodipine 5 mg
- Volunteers
- 64 people
- Sponsor
- Research Institute for Complex Problems of Cardiovascular Diseases, Russia
Venous Leg Ulcer, Diabetic Foot
AQUACEL® Ag+ Extra™ and Cutimed™ Sorbact® Dressing in the Management of Venous Leg Ulcers Over a 12-week Period
Study is to provide evidence comparing AQUACEL® Ag+ Extra™ versus Cutimed® Sorbact® in the progression of wounds towards healing
- Trial name
- NCT05892341
- Testing
- AQUACEL® Ag+ Extra™, Cutimed® Sorbact®
- Where
- 18 sites in Colombia, Germany and 1 more
- Volunteers
- 203 people
- Sponsor
- ConvaTec Inc.
Neovascular Age-related Macular Degeneration (nAMD)
Study to Evaluate the Safety and Effectiveness of Intravitreal Injections (IVI) of Brolucizumab in Patients With Neovascular Age-related Macular Degeneration (nAMD)
The purpose of this study was to generate additional safety and effectiveness data in Indian neovascular age-related macular degeneration (nAMD) patients that more closely resemble the real-world population intended to be treated…
- Trial name
- NCT05269966
- Testing
- Injection Brolucizumab
- Where
- 10 sites in India
- Volunteers
- 105 people
- Sponsor
- Novartis Pharmaceuticals
Cardiovascular Disease
A New Operation for the Treatment for Long-standing Atrial Fibrillation
Atrial fibrillation(AF) often occurs in patients with mitral valve disease. Both mitral replacement and mitral valve plasty are the effective methods to the mitral valve disease.
- Trial name
- ANOLAF (NCT03347695)
- Testing
- Left Atrial Geometric Volume Reduction, Pulmonary Vein Island Isolation and Left Appendage Base Closure(selected patients), Left Atrial Geometric Volume Reduction, Pulmonary Vein Island Isolation and Left Appendage Base Closure
- Where
- China
- Volunteers
- 140 people
- Sponsor
- Fujian Medical University
Chronic Venous Insufficiency
Radiofrequency Ablation vs Laser Ablation of the Incompetent Greater Saphenous Vein
The aim of this study is to perform a randomized, prospective trial comparing the two current methods of treatment for chronic venous insufficiency, in an effort to evaluate complications and outcomes for each method, and…
- Trial name
- NCT02236338
- Testing
- Ablation of the Incompetent Greater Saphenous Vein, ClosureFAST radiofrequency catheter, EVLT 980nm diode laser system
- Where
- United States
- Volunteers
- 200 people
- Sponsor
- Virginia Commonwealth University
Venous Thrombosis
Comparison of Arixtra vs. Lovenox to Prevent Blood Clots in Medically Ill Patients
A total of 50 patients >40 yrs of age with an expected hospital stay in the Medical Intensive Care or Regional Heart Unit at LVH Muhlenberg of 6 days or longer will be enrolled.
- Trial name
- BRiEF (NCT00521885)
- Testing
- Arixtra (Fondaparinox) 2.5 mg SC Daily, Lovenox 40mg SC Daily
- Where
- United States
- Volunteers
- 1 people
- Sponsor
- Lehigh Valley Hospital
Upper Extremity Deep Vein Thrombosis, Central Venous Catheter Thrombosis
Thromboprophylaxis With Rivaroxaban In Patients With Malignancy and Central Venous Lines
Purpose of the Pilot Trial: To determine the feasibility of conducting a multicentre randomized open label controlled trial evaluating the use of prophylactic dose rivaroxaban to prevent central venous catheter (CVC) associated…
- Conditions
- Upper Extremity Deep Vein Thrombosis, Central Venous Catheter Thrombosis, Cancer
- Trial name
- TRIM-Line (NCT03506815)
- Testing
- Rivaroxaban 10 MG
- Where
- Canada
- Volunteers
- 105 people
- Sponsor
- Ottawa Hospital Research Institute
Venous Thromboembolism
The Use of Fondaparinux in Preventing Thromboembolism in High Risk Trauma Patients
Trauma patients are at high risk of developing deep vein thrombosis (DVT) and pulmonary embolism (PE). The incidence of DVT varies greatly from 5-63% among studies depending on patient's individual risk factors, modality of…
- Trial name
- NCT00531843
- Testing
- fondaparinux sodium, sequential compression devices
- Where
- United States
- Volunteers
- 105 people
- Sponsor
- Mary Knudson, M.D.